Invesco NASDAQ 100 ETF (QQQM) Stock Price Today
Aura AI Summary
Key Stats
- $111.60BMarket Cap
- 3,716,107Volume
- Broad Market / FactorSector
- $312.7652W High
- $229.8752W Low
- 56 DaysTypical Hold Time
- -Enterprise Value
- -Div Yield
- 28% Sell | 72% BuyTrading Activity
Track Invesco NASDAQ 100 ETF (QQQM) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Invesco NASDAQ 100 ETF has traded between a low of $229.87 and a high of $312.76, highlighting its annual price range. Buy and sell Invesco NASDAQ 100 ETF shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Most Recent News
UBS Group AG surpasses 5% ownership in Bang & Olufsen shares as of October 9, 2026
UBS Group AG has officially notified that it holds 7,768,727 shares in Bang & Olufsen A/S, representing 5.27% of the company's total share capital and voting rights as of October 9, 2026. This disclosure is made in compliance with the Danish Capital ...

FDA approves Roche’s Enspryng as first at-home treatment for thyroid eye disease
The FDA has approved Roche's Enspryng (satralizumab) as the first and only at-home subcutaneous treatment for adults with thyroid eye disease (TED). This approval follows positive results from Phase III SatraGO-2 trials showing significant reductions...

IP Group invests £4m as Microbiotica raises £36m to advance ulcerative colitis drug to Phase 2 trials
IP Group PLC has invested £4 million in a £36 million Series C funding round for Microbiotica, supporting the development of its ulcerative colitis treatment, MB310. The funding, led by British Business Bank, will enable Microbiotica to progress MB31...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.